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Summary
Apolipoprotein-E £4 (APOE-E4) has been consistently as-
sociated with Alzheimer disease (AD) and may be responsi-
ble for an earlier age at onset. We have previously reported
a diminished association between APOE-E4 and AD in
African Americans. Using a new method, which allows
inclusion of censored information, we compared relative
risks by APOE genotypes in an expanded collection of
cases and controls from three ethnic groups in a New
York community. The relative risk for AD associated with
APOE-E4 homozygosity was increased in all ethnic groups
(African American relative risk [RR] = 3.0; 95% confi-
dence interval [Cfl = 1.5-5.9; Caucasian RR = 7.3, 95%
CI = 2.5-21.6; and Hispanic RR = 2.5, 95% CI = 1.1-
5.7), compared with those with APOE-E3/I3 genotypes.
The risk was also increased for APOE-44 heterozygous
Caucasians (RR = 2.9, 95% CI = 1.7-5.1) and Hispanics
(RR = 1.6, 95% CI = 1.1-2.3), but not for African Ameri-
cans (RR = 0.6, 95% CI = 0.4-0.9). The age distribution
of the proportion of Caucasians and Hispanics without
AD was consistently lower for APOE-E4 homozygous and
APOE-44 heterozygous individuals than for those with
other APOE genotypes. In African Americans this relation-
ship was observed only in APOE-E4 homozygotes. These
results confirm that APOE genotypes influence the RR of
AD in Caucasians and Hispanics. Differences in risk
among APOE-E4 heterozygote African Americans suggest
that other genetic or environmental factors may modify
the effect of APOE-E4 in some populations.
Received July 20, 1995; accepted for publication November 20,
1995.
Address for correspondence and reprints: Dr. Richard Mayeux, The
Gertrude H. Sergievsky Center, Columbia University College of Physi-
cians and Surgeons, 630 West 168th Street, New York, NY 10032.
E-mail: rpm2@columbia.edu
© 1996 by The American Society of Human Genetics. All rights reserved.
0002-9297/96/5803-0016$02.00
Introduction
The presence of the F4 allele of the apolipoprotein-E
gene (APOE) has been consistently associated with an
increased risk of Alzheimer disease (AD) (Borgaonkar
et al. 1993; Corder et al. 1993, 1994; Mayeux et al.
1993; Noguchi et al. 1993; Payami et al. 1993; Poirier
et al. 1993; Saunders et al. 1993a, 1993b; Strittmatter
et al. 1993a, 1993b; Chartier-Hardlin et al. 1994; Kuu-
sisto et al. 1994; Liddell et al. 1994; Roses et al. 1994;
Sorbi et al. 1994; Hendrie et al. 1995; Maestre et al.
1995). However, it is apparent that the APOE-e4 allele
alone is neither necessary nor sufficient to cause the
disease, because (1) AD develops in the absence of
APOE-e4 (Lannfelt et al. 1994; Maestre et al. 1995) and
(2) some individuals escape the disease despite having an
APOE-e4 allele. The presence of APOE-e2 has been
associated with both a decreased (Corder et al. 1994;
Chartier-Hardlin et al. 1994) and an increased risk of
AD (Lannfelt et al. 1994; Maestre et al. 1995; van Duijn
et al. 1995).
Roses et al. (Roses et al. 1994; Roses 1995) have ex-
plained the variability by proposing that APOE geno-
types influence the age at onset of AD. In both familial
and sporadic AD, they observed an earlier age at onset
among APOE-e4 homozygous and APOE-e4 heterozy-
gous AD cases than among those AD cases with other
APOE genotypes. These observations have needed con-
firmation, because they imply that APOE genotypes may
predict specific age-at-onset distributions. Commercial
tests based on the APOE allele system have become
available, allowing physicians to estimate the risk of AD
and the average age at onset, by APOE genotype.
There may be important limitations, however. The
association between AD and APOE--4 is less consistent
for individuals >80 years of age (Poirier et al. 1993;
Roses et al. 1994), when disease risk is highest (Evans
et al. 1989; Gurland et al. 1995; Hebert et al. 1995),
and the association may be stronger in women than in
men (Payami et al. 1994). The relationship between AD
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and APOE-e4 in ethnic groups other than Caucasians
has not been thoroughly examined. For example, an
association between AD and APOE-e4 homozygosity,
but not between AD and APOE--4 heterozygosity, was
observed in African Americans in New York (Maestre
et al. 1995), whereas both APOE-e4 homozygosity and
APOE-e4 heterozygosity were associated with AD
among African Americans in Indiana (Hendrie et al.
1995).
In this investigation we developed a new method to
estimate relative risk (RR) of AD among individuals,
with incomplete observations based on APOE geno-
types in an expanded elderly group of African Ameri-
cans, Hispanics, and Caucasians residing in the Wash-
ington Heights community of New York City. We also
used a previously published method (Turnbull 1974) to
plot the age distribution of the proportion of individuals




All data were derived from individuals residing in the
same community. AD cases were identified as part of a
comprehensive community-based registry of all demen-
tias in northern Manhattan. We used information (clini-
cal and billing records, the computerized daily census,
monthly discharge lists, and the daily logs) from a num-
ber of sources, medical as well as nonmedical: regional
hospitals (including inpatient and outpatient services),
private practitioners and the single neurologist unaffili-
ated with the Columbia Presbyterian Medical Center,
federal and state health agencies offering assistance to
individuals in the area, nursing homes and other health-
related facilities, an HMO (Health Insurance Plan of
Greater New York), and all senior-citizen centers in the
community. A list of individuals with home-health-care
attendants in the community was obtained from the Hu-
man Resources Administration in New York City. All
individuals were screened to identify those with and
without cognitive impairment, as described elsewhere
(Gurland et al. 1995). Those with, and a proportion of
those without, cognitive impairment were examined for
the presence or absence of AD. Controls were volunteers
recruited from the same community, but most were iden-
tified in senior-citizen centers and not in medical facili-
ties. As with AD cases, all controls at each community
site were informed about a study of aging and health
and were asked to participate. All controls received in-
terviews and clinical assessments identical to those used
for AD cases. The refusal rate, for both AD cases and
controls identified at these centers, was <20%.
AD cases and controls were also identified from a
random survey of Medicare recipients in the same geo-
graphic area (the population >65 years of age was
9,349; United States Bureau of the Census 1991). The
Health Care Financing Administration (HCFA) pro-
vided access to a random sample of the names and ad-
dresses of recipients within three contiguous ZIP codes
in the community. Potential subjects were sent a letter
from HCFA that explained that they had been randomly
selected as candidates for a study of aging. A 90-min
in-person interview was conducted for those who agreed
to participate, followed by a complete medical and neu-
rological assessment by a physician. Names of AD cases
and controls identified in the survey and the registry
were cross-referenced to eliminate duplicates. Participa-
tion rate was 68% in the HCFA-based random sample
and did not differ by ethnic group or gender.
The Columbia University institutional review board
reviewed and approved this project. All individuals pro-
vided written informed consent. Both AD cases and con-
trols were followed over a 4-year period.
Diagnosis ofAD
Physicians elicited the medical history and conducted
a standardized physical and neurological examination.
Whenever possible, all ancillary information, including
medical charts and reports of laboratory studies, were
used in the evaluation. A standardized neuropsychologi-
cal battery measuring performance in memory, orienta-
tion, abstract reasoning, language, and construction was
administered. Independence in activities of daily living
was measured to determine whether subjects met func-
tional criteria for dementia. Except for APOE geno-
types, all clinical information was reviewed at a diagnos-
tic conference of physicians and neuropsychologists, to
arrive at a consensus diagnosis based on research criteria
(McKhann et al. 1984; American Psychiatric Associa-
tion 1987). The development of our diagnostic methods
in relation to the cultural and educational demographics
of this community has been described elsewhere (Pitt-
man et al. 1992; Stern et al. 1992). The reliability and
consistency of these assessments have also been reported
elsewhere (Schofield et al., in press). The majority of AD
cases were alive at the time of this investigation, but data
were also available from 16 AD cases with postmortem
confirmation of AD that were from the same commu-
nity.
Age at Onset
Although all informants for prevalent AD cases were
asked about the duration of symptoms, we did not at-
tempt to estimate the age at onset in these individuals,
because of the difficulty in substantiating this type of
information. To improve validity, we censored (left-cen-
sored) the age at onset in prevalent AD cases, on the
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basis of methods described elsehwere (Turnbull 1974;
Cupples et al. 1991; Tang et al., in press). In brief, for
each prevalent case, the EM (expectation and maximiza-
tion) algorithm, as implemented by Turnbull, was used
to compute the expected age at onset (see appendixes).
This value was less than the patient's age on entry into
the study and was within an age interval based on the
distribution of ages either (1) at study entry, for all
younger prevalent AD cases, or (2) ages at onset, for all
younger incident AD cases. In the age interval, the low-
est age for Caucasians and Hispanics was 50 years,
whereas in African Americans the lowest age was 59
years. We used age 50 years as the lowest age for com-
puting the expected age at onset for all prevalent AD
cases, regardless of ethnic group. For example, in a pa-
tient with AD who was 75 of age, the estimated age at
onset would be 50-75 years. Several controls in the
registry became demented during the 4-year follow-up.
The age at onset for these AD cases was their age on
the date at which dementia was first documented. For
controls, we right-censored at their age at the last fol-
low-up examination.
Ethnic Group
Ethnic group was classified by self-report using the
format of the 1990 United States Bureau of the Census
(1991). This allows each individual to identify himself
as belonging to a particular racial or ethnic group. Each
individual is then asked whether he or she is of "His-
panic" origin. Using this information, we separated sub-
jects into three ethnic groups: African American, His-
panic, and Caucasian (non-Hispanic), according to self-
report, on the basis of direct interview with the subject
or, if the individual was demented, a family member.
APOE Genotyping
Genomic DNA was amplified by PCR and was sub-
jected to CfoI restriction analysis using APOE primers
and conditions modified from those described by Hixson
and Vernier (1991). Genotypes were determined with-
out knowledge of patient-control status.
Data Analysis
APOE allele frequencies were determined by counting
alleles and calculating sample proportions. For compari-
son across ethnic groups, APOE allele frequencies were
calculated by use of data from all controls and from a
random 10% sample of the AD cases within each ethnic
group, to create a representative population of individu-
als -65 years of age that would include patients with
AD (Evans et al. 1989). For comparison of AD cases
and controls, within and across ethnic groups, APOE
allele frequencies were calculated for all subjects and
were compared by X2 analysis (Fleiss 1981).
We used an iterative method (i.e, the EM algorithm)
to obtain the nonparametric maximum-likelihood esti-
mates of the age-at-onset distributions, by APOE geno-
types, within each ethnic group, from the "self-consis-
tent equation" (Kaplan and Meier 1958; Turnbull 1974;
present study, appendix A). A parametric approach was
used to develop a proportional hazards regression model
to estimate the RR for AD, by APOE genotype (refer
to appendix B). This analysis was similar to the method
used by Cupples et al. (1989, 1991). Both univariate
and multivariate RRs for AD associated with various




Data were available for 305 patients with AD and for
485 nondemented healthy elderly. Some 55% of the
patients with AD were identified through the registry,
compared with 45% from the survey. Some 31% of the
controls were volunteers from the community sites, and
69% were identified through the survey. Patients and
controls differed by gender (76% of AD cases were
women, vs. 67% of controls; X2 = 6.8, P < .01). In all
ethnic groups combined, AD cases were older (76.4
± 9.1 years [range 46-96 years]) than controls (72.9
± 6.7 years [range 46-93 years]; P < .05). African
Americans and Hispanics were generally older and less
well educated than Caucasians (table 1). African-Ameri-
can and Hispanic AD cases also had less education than
controls (7.3 ± 5.0 years for AD cases, vs. 9.0 ± 4.6
years for controls; P < .05).
APOE Allele Frequencies
Overall, the APOE allele frequencies differed signifi-
cantly among the three ethnic groups (data not shown;
X = 19.7; P < .0005). The main difference was in the
frequency of APOE-e4 among African Americans,
which was most pronounced among individuals >72
years of age (median age), in whom the frequency of
APOE-e4 was .21, compared with .09 both in Cauca-
sians and in Hispanics (table 2). APOE allele frequencies
did not differ by gender.
Among AD cases, the distribution of APOE alleles
also differed across ethnic groups (X2 = 11.9, df 4, P
< .01), with higher frequencies of APOE-e4 in Cauca-
sians (27%) than in African Americans (23%) or His-
panics (19%) and with higher frequencies of APOE-e2
in African Americans (11%) than in the other two ethnic
groups (Caucasians, 3%; and Hispanics, 7%), as noted
in table 1. In Caucasians and Hispanics, but not in Afri-
can Americans, the APOE-e4 allele frequency was sig-
nificantly higher among AD cases than among controls.
576
Tang et al.: APOE-Based Risk of Alzheimer Disease
Table 1




ETHNIC GROUP (N) (years) (years) APOE-63 APOE-e4 APOE-e2
African American:
AD cases (106) 78 ± 7.6 7.4 ± 4.0 .66 .23 .11
Controls (154) 74 ± 5.8a 9.4 ± 3.8a .73 .20 .07
Caucasian:
AD cases (59) 71 ± 9.1 13.4 ± 4.2 .70 .27 .03
Controls (112) 72 ± 8.5 12.3 ± 4.0a .84 .09 .07
Hispanic
AD cases (140) 77 ± 8.3 4.8 ± 3.7 .74 .19 .07
Controls (219) 73 ± 6.1 7.0 ± 4.3a .83 .10 .07
NoTE.-Allelic frequencies differed significantly between AD cases and controls, within and across ethnic
groups; for explanation, see the text.
a Significant difference (P < .05) exists within each stratum.
When the groups were subdivided into age quartiles,
however, APOE-s4 frequency in African-American AD
cases in the youngest quartile (age -69 years) differed
significantly from that in controls in the youngest
quartile (42% in AD cases, vs. 15% in controls), because
of a greater number of APOE-e4 homozygotes in this
age group. In the three other quartiles, African-Ameri-
can AD cases and controls had nearly identical APOE-
£4 frequencies.
RR and the Age-at-Onset Distribution
The impact of APOE genotypes on RR was calcu-
lated, and the cumulative age-at-onset distributions were
Table 2
APOE Allele Frequency, by Age and Ethnic Group
FREQUENCY (No. Counted)
ETHNIC GROUP APOE-E3 APOE-e4 APOE-e2
African American:
<72 years of age .72 (107) .20 (27) .08 (12)
>72 years of agea .74 (136) .21 (38) .05 (10)
Caucasian:
-72 years of age .84 (112) .10 (13) .06 (9)
>72 years of age .85 (87) .09 (9) .06 (6)
Hispanic:
G72 years of age .81 (193) .11 (26) .08 (19)
>72 years of age .86 (195) .09 (21) .05 (12)
NoTE.-To compare ethnic groups across ages, we used all controls
recruited and a 10% random sample of cases from each ethnic group,
to form a representative sample of elderly ¢65 years of age.
aX2 = 19.7, df = 4, P < .0005. APOE allele frequencies differ in
African Americans relative to other ethnic groups >72 years of age,
the median age of the cohort.
plotted for each ethnic group. Specific APOE genotypes
for AD cases and controls, for each ethnic group, are
shown in table 3. African Americans homozygous for
the APOE-e4 allele had a significantly increased risk of
AD (RR = 3.0, 95% CI = 1.5-5.9) compared with
African Americans with APOE-e3/s3 genotypes, but the
risk associated with APOE-e4 heterozygosity was sig-
nificantly decreased (RR = 0.6, 95% CI = 0.4-0.9). The
proportions, by age and APOE genotype, of individuals
without AD are shown in figure 1. We isolated individu-
als with APOE-e4 homozygosity and individuals with
APOE-e4 heterozygosity, to show the differences be-
tween the age distributions in the proportion remaining
unaffected, compared with other APOE genotypes.
Caucasians, both those APOE-e4 homozygous and
those APOE-s4 heterozygous, had a significantly in-
creased RR for AD (£4 homozygosity RR = 7.3, 95%
CI = 2.5-21.6; and £4 heterozygosity RR = 2.9, 95%
CI = 1.7-5.1), compared with Caucasians with APOE-
e3/e3 genotypes. Hispanics with one or more copies of
the APOE-e4 allele also had higher RRs of AD (£4 ho-
mozygous RR = 2.5, 95% CI = 1.1-5.7; and £4 hetero-
zygous individuals RR = 1.6, 95% CI = 1.1-2.3), com-
pared with Hispanics with APOE-e3/e3 genotypes.
Figures 2 and 3 illustrate the age distribution of the
proportion of individuals without AD, comparing those
with at least one APOE-e4 allele to those with other
APOE genotypes, among Caucasians and Hispanics.
We also examined the protective effect of APOE ge-
notypes with one or more e2 alleles, again using APOE-
e3/s3 genotypes as the reference. The disease risk associ-
ated with APOE-e2 was lower among Caucasians (RR
= 0.2, 95% CI 0.03-1.7), but not in African Americans
(RR = 1.3, 95% CI = 0.8-2.3) or Hispanics (RR = 1.0,
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Table 3
APOE Genotypes in AD Cases and in Controls, by Ethnic Group
No. (Proportion) OF INDIVIDUALS
ETHNIC GROUP E3N3 e2/e3 e2/e2 E4/E2 e3/e4 E4/£4
African American:
AD cases 49 (.46) 16 (.151) 3 (.028) 2 (.019) 26 (.245) 10 (.094)
Controls 77 (.50) 16 (.104) 1 (.006) 3 (.019) 55 (.357) 2 (.013)
Caucasian:
AD cases 30 (.508) 1 (.017) 0 2 (.034) 22 (.373) 4 (.068)
Controls 78 (.696) 14 (.125) 0 1 (.009) 19 (.17) 0
Hispanic:
AD cases 80 (.571) 12 (.086) 1 (.007) 5 (.036) 36 (.257) 6 (.043)
Controls 148 (.676) 29 (.132) 1 (.015) 0 38 (.174) 3 (.014)
95% CI = 0.5-1.7). Each analysis was repeated, with
either stratification by gender or inclusion of educational
level as a covariate; but the results were unchanged.
We also examined differences between the number of
individuals either left- or right-censored and the number
of those with complete information, by APOE genotype
and ethnic group; there were no statistically significant
differences, in the number of individuals, by APOE ge-
notype, but incident AD cases were significantly more
numerous among African Americans and Hispanics than
among Caucasians (table 4).
Discussion
We examined the RR for AD, on the basis of APOE
genotypes among three distinct ethnic groups residing
in New York City, using a new method that included
both left- and right-censored observations. Using this
method, we also plotted the age distribution of the pro-
portions of individuals within each ethnic group re-
maining free of AD, by APOE genotype. As expected,
the APOE-E4/c4 genotype was associated with the high-
est RR for AD in all three ethnic groups, compared
with individuals with the APOE-E3/s3 genotype. Among
Caucasians and Hispanics, APOE-e4 heterozygosity
was also associated with a significantly higher RR for
AD, compared with individuals with the APOE-e3/e3
genotype. However, among African Americans, APOE-
e4 heterozygotes had a significantly lower RR for AD,
compared with individuals with the APOE-e3/63 geno-
type. Stratification by gender or educational level did
not change the associations between APOE-e4 and AD
in any ethnic group. There was only minimal evidence
that AD risk was reduced for Caucasians with APOE-E2
genotypes, and there was no decrease in risk for African
Americans or Hispanics with these genotypes.
An association between APOE-e4 and AD has been
reported among African Americans in Indiana (Hendrie
et al. 1995). African Americans were also included in a
North Carolina study (Saunders et al. 1993a), but the
specific association between APOE-e4 and AD was not
described. In both studies the APOE-e4 frequency was
lower than that reported here; in Indiana the APOE-E4
allele frequency in controls was .12, whereas in North
Carolina study the APOE-e4 frequency was .17 overall.
No association between APOE-e4 and AD was found
in a small study of elderly Nigerians (Osuntokun et al.
1995), where the £4 allele frequency in the control popu-
lation was .26. Differences in APOE allele frequencies
by ethnic group are well established in adults and chil-
dren (Davignon et al. 1988; Kamboh et al. 1989; Sepehr-
nia et al. 1989; Hallman et al. 1991; Srinivasan et al.
1993; Sandholzer et al. 1995; Zekraoui et al. 1995).
Regional differences in the frequency of APOE alleles
among African populations have also been described
(Sepehrnia et al. 1989; Sandholzer et al. 1995; Zekraoui
et al. 1995). Zekraoui et al. (1995) observed the APOE-
s4 frequency to vary from .03 among Wolof in Senegal
to .38 among Tutsi in Burundi, and a similarly elevated
e4 frequency (.4) was also observed in South African
bushman (Sandholzer et al. 1995). The APOE-s4 allele
frequency among the African Americans in the present
study and others (Kamboh et al. 1989; Srinivasan et
al. 1993) was 20%-26%. Thus, it is possible that the
individuals included in our study were genetically dis-
tinct from those in the Indiana study. It is also important
to note that the APOE-E4 frequency did not decline with
age, in contrast to the trend noted among Caucasians
in the United States and Europe (Kervinen et al. 1994;
Louhija et al. 1994; Schachter et al. 1994).
The decline in the frequency of APOE-E4 with age in
Caucasians has been attributed to mortality from heart
disease (Eichner et al. 1993; Kervinen et al. 1994; Luc et







Figure 1 Proportion of individuals without AD, among African Americans, by APOE genotypes. APOE genotypes are divided into three
groups: APOE-e4 homozygosity, APOE-e4 heterozygosity, and all other APOE genotypes as the reference. We retained three groups only
among African Americans, to demonstrate the different effects of APOE homozygosity and APOE heterozygosity.
variations in the APOE locus are associated with choles-
terol and triglyceride concentrations (Davignon et al.
1988; Reilly et al. 1992; Louhija et al. 1994). For example,
in young and middle-aged Finns the allele frequency of
APOE-e4 is -.2, and it decreases by almost 50% with age,
because of heart disease (Kuusisto et al. 1994; Stengard et
al. 1995), but a strong association between AD and
APOE-e4 persists (Kuusisto et al. 1994).
In contrast, APOE-e4 does not consistently predict
cholesterol or triglyceride concentrations in adults or
children of African origin (Sepehrnia et al. 1989; Sriniva-
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Figure 2 Proportion of individuals without AD, among Caucasians, by APOE genotypes. APOE genotypes are divided into two groups:
those with any APOE-e4 and all other APOE genotypes as the reference. For the method used, see the text.
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Figure 3 Proportion of individuals without AD, among Hispanics genotypes. APOE genotypes are divided into two groups: those with
any APOE-e4 and all other APOE genotypes as the reference. For the method used, see the text.
1995). Age-related changes in the population frequency
of APOE-s4 in African Americans have not been thor-
oughly investigated, but the frequency in our study re-
mained elevated among the individuals >80 years of
age. This suggests that the relationship of APOE-e4 to
heart disease, longevity, and AD in African Americans
may not parallel the relationship in Caucasians. Alterna-
tively, other genes or environmental factors, which are
Table 4
unique to African Americans, may have a greater influ-
ence on mortality and survival.
Given the consistent association between APOE-e4
heterozygosity and AD, seen both in the literature and
among Caucasians and Hispanics in the present study,
we considered the possibility of a systematic bias in our
investigation of African Americans. The vast majority
of African-American AD cases and controls were born
Individuals with Prevalent AD, Individuals Who Are Not Demented, and Individuals with Incident AD,
by APOE Genotype and Ethnic Group
No. (Proportion) OF INDIVIDUALS
ETHNIC GROUP £3/£3 -2/e3 £2/e2 £4/£2 £3/£4 E4/e4
African American:
Prevalent-AD cases 23 (.41) 10 (.179) 2 (.036) 2 (.036) 13 (.232) 6 (.107)
Not demented 77 (.50) 16 (.104) 1 (.006) 3 (.019) 55 (.357) 2 (.013)
Incident-AD cases 26 (.52) 6 (.12) 1 (.02) 0 13 (.26) 4 (.08)
Caucasian:
Prevalent-AD cases 23 (.46) 1 (.02) 0 2 (.04) 21 (.42) 3 (.06)
Not demented 78 (.696) 14 (.125) 0 1 (.009) 19 (.17) 0
Incident-AD cases 7 (.778) 0 0 0 1 (.11) 1 (.11)
Hispanic:
Prevalent-AD cases 40 (.556) 6 (.083) 1 (.014) 2 (.028) 21 (.292) 2 (.028)
Not demented 148 (.676) 29 (.132) 1 (.005) 0 38 (.174) 3 (.104)
Incident-AD cases 40 (.588) 6 (.088) 0 3 (.044) 15 (.221) 4 (.059)
NOTE.-There was a difference in the no. of individuals with incident AD, by ethnic group (X2 = 21.1, df = 4, P < .001); Caucasians had
fewer individuals.
580
Tang et al.: APOE-Based Risk of Alzheimer Disease
in the United States and have resided in its northeastern
region for most of their adult lives. The two methods
used to identify patients with AD and controls (a com-
munity-based registry and a survey of a random sample
of Medicare recipients) identified a representative popu-
lation, both healthy and diseased, of African Americans,
Caucasians, and Hispanics residing in the community.
Despite the fact that this is one of the larger studies of
APOE and AD, the infrequency of subjects with certain
APOE genotypes, such as E2/e2, makes some of our
conclusions tentative. We have previously investigated
the methods used to establish the diagnosis of AD both
among individuals from different cultures and among
individuals with lower educational attainment (Pittman
et al. 1992; Stern et al. 1992). Our methods appear to
be as free of bias as is possible (Gurland et al. 1995).
Two African Americans were among the postmortem
AD cases included in this investigation; a single patient
was APOE-E4/e4, and another was APOE-e2/e3. In the
data analyses, we adjusted for gender and education
as potential confounders, but this did not change our
primary observations. Further, we have been unable to
attribute the lower AD risk associated with APOE-s4
heterozygosity to comorbidity from heart disease (Chun
et al. 1995).
For the estimation of RR, more complete information
was available from African Americans and Hispanics
than was available from Caucasians. Although the maxi-
mum-likelihood method does not depend on the pres-
ence of uncensored information, the estimates of RR
would have improved if we had had more complete in-
formation.
Therefore, we consider it possible that some as yet
unidentified genetic or environmental factor reduces the
risk of AD among APOE-e4 heterozygous African
Americans. Alternatively, genetic variations in other
proteins that interact with apolipoprotein E directly or
indirectly at the cellular level might account for the ob-
servations in the present study. Because APOE-e4
heterozygosity (primarily APOE-e4/e3) occurs in
-25%-30% of most populations in the United States
and Europe (Davignon et al. 1988), understanding this
protective effect, whether genetic or environmental,
would seem an important point of investigation.
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Appendix A
Estimating the Survival Distribution of Age at Onset
Let X be the age at onset of AD, and let
age at first visit, if it was prevalent AD;
age at last visit, if it was not AD;
Y =
age at onset, if it was newly diagnosed
or incident AD, where age
at onset is known .
We can express the available information on X by a pair
of random variables (YA), where
0, if X < Y (left-censored);
A = if X > Y (right-censored);
2, if X = Y (uncensored) .
Our goal is to estimate the survival distribution function
S(x) = 1 - F(x) = P(X > x) of X from a sample of n
independent pairs (yj,6j), i = 1, - ., n.
Turnbull (1974) proved that the nonparametric maxi-
mum-likelihood estimate (NMLE) S satisfies the follow-
ing "empirical self-consistent equation":
S(x) = S (x) + S1(X) + S2(x)
- fX S(X) dSI(t) + r
_S(x) dSo(t),
where
S.(x (yj > x, 8j = i ), i = O. 1, 2 5j=1
and the indicator function 1(0) is defined by
I(y,> x, = i)1' if y x or6, *i;1, if y, > x and 6, = i.
581
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Therefore the NMLE S is also called a "self-consistent




Regression models proposed in survival analysis often
involve the assumption of proportional hazard func-
tions; that is, h(xz) = r(I'z)ho(x ), where h(x,z) is the
hazard function for a subject with a p vector measure
of covariates z. r(I'z) expresses the relationship between
z and regression parameter P and can be interpreted as
RR. ho(x) is the hazard function of the underlying fail-
ure-time distribution. In some AD cases ho(x) has simple
a form, ho(x) = h (constant) if the underlying distribu-
tion is exponential, whereas ho(x) = ?Xxc for Weibull
distribution (Lawless 1982, p. 16). The most commonly
used proportion function is r(r'z) = exp(p'z). The as-
sumption can be empirically checked by using computer-
graphic displays.
The parameters in the regression model are composed
of two parts; one is the parameter P involved in the
proportion function, and the other one, 0, characterizes
the underlying distribution. The model parameter il
= (0,4) can be estimated by the maximum-likelihood
method.
If it is assumed that there are no uncensored AD cases,
the likelihood function can be written as
n
L(0, N) = f S(YM, 0, f6i[1 - S(YM, 0, P)]' i.
i= 1
With the proportional hazard model, the score func-
tion, which is the first derivative of the log likelihood,
is
Q1( A) _a log L(0,j3)
5.- S(Yi; 0, a)ef'zs log So(yi; 0)z.
i1 1 - S(Yi; 0, e) a
Q2 a A) (9 log L(0) P)
=
I
~ epZi log SO(Yi; O)zi .
where So is the underlying survival function. The maxi-
mum-likelihood estimate r1 can be obtained by numeri-
cally solving the equation Q = 0. The asymptotic vari-
ance of 1q is estimated by the inverse of the observed
information matrix of second partials of the log likeli-
hood for Newton's method (Isaacson and Keller 1966,
p. 97). Note that, when X has Weibull or exponential
distribution (a special case of y = 1), the proportion
hazard model is h(x,z) = X x" eO'z. The score function
can be simplified as




S(y,; i) = exp[-exp(,n'z,)],
'n = [log(x), y, 5), and ' = (1, log yi, z']
The stated method can be easily modified for the data
that include the uncensored AD cases.
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